Drugs / SCB-2019
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04932824 | Jan → Nov 2021 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05087368 | Dec 2021 → Apr 2022 | COVID-19 | D'Or Institute for Research and Education | Unknown | No outcome recorded |
| Phase 2 | NCT04954131 | Aug → Nov 2021 | COVID-19 | Zhejiang Clover Biopharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05193279 | Oct → Dec 2022 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT04672395 | Mar 2021 → Sep 2022 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05812586 | Mar → Jun 2023 | COVID-19 | D'Or Institute for Research and Education | Unknown | No outcome recorded |
| Phase 3 | NCT05188677 | Jun 2022 → Jun 2023 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Completed | No outcome recorded |
| Phase 3 | NCT05012787 | Nov 2021 → Mar 2022 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05228314 Comparator | May → Sep 2022 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Completed | No outcome recorded |
| Phase 1 | NCT04405908 Comparator | Jun 2020 → Oct 2021 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06567457 Comparator | Oct 2023 → Sep 2024 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Withdrawn | No outcome recorded |
| Phase 3 | NCT05926440 Comparator | Aug 2023 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCB 2019 | “This study is to evaluate the safety and immunogenicity of the investigational CpG 1018/Alum-adjuvanted recombinant SARS-CoV-2 trimeric S-protein subunit vaccine (SCB 2019)...” NCT05012787 ↗ |
| Known as | S-Trimer | “Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.” PMID 33524311 ↗ Jan 2021 |
| Modality | Vaccine | “a protein subunit vaccine candidate for COVID-19” PMID 33524311 ↗ Jan 2021 |
| Route | Intramuscular | “SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22).” NCT04405908 ↗ |